Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016146979 - ANTIBODIES AGAINST MODIFIED INSULIN FOR USE IN TREATMENT OF AND ASSAYS FOR DIABETES

Publication Number WO/2016/146979
Publication Date 22.09.2016
International Application No. PCT/GB2016/050678
International Filing Date 11.03.2016
IPC
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
G01N 2333/62
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
575Hormones
62Insulins
G01N 2800/042
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
04Endocrine or metabolic disorders
042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/6854
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6854Immunoglobulins
Applicants
  • QUEEN MARY UNIVERSITY OF LONDON [GB]/[GB]
Inventors
  • NISSIM, Ahuva
  • POZZILLI, Paolo
  • STROLLO, Rocky
Agents
  • BASSIL, Nicholas, Charles
Priority Data
1504297.113.03.2015GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES AGAINST MODIFIED INSULIN FOR USE IN TREATMENT OF AND ASSAYS FOR DIABETES
(FR) ANTICORPS CONTRE L'INSULINE MODIFIÉE UTILES DANS LE TRAITEMENT DU DIABÈTE ET LE DÉPISTAGE DU DIABÈTE
Abstract
(EN)
The present invention provides a method of diagnosing type 1 diabetes (T1D) or latent autoimmune diabetes in adults (LADA) in a subject comprising testing a sample from the subject for the presence or absence of antibodies against modified insulin, wherein the presence of antibodies against modified insulin in the sample is indicative of T1D or LADA in the subject. The invention also provides a method of treating T1D or LADA in a subject in need thereof. Also provided are methods of determining the10 therapeutic effectiveness of a therapeutic agent in treating T1D or LADA in a subject diagnosed with T1D or LADA. A kit for diagnosing T1D or LADA in a subject comprising reagents for determining the presence of antibodies against modified insulin in a sample from a subject is also provided.
(FR)
La présente invention concerne un procédé permettant de diagnostiquer le diabète de type 1 (T1D) ou le diabète auto-immun latent chez l'adulte (LADA) chez un sujet consistant à déterminer dans un échantillon du sujet la présence ou l'absence d’anticorps contre l'insuline modifiée, la présence d'anticorps contre l'insuline modifiée dans l'échantillon indiquant un T1D ou un LADA chez le sujet. L'invention concerne également un procédé de traitement du T1D ou du LADA chez un sujet en ayant besoin. L'invention concerne également des procédés de détermination de the10 l'efficacité thérapeutique D'un agent thérapeutique dans le traitement de Diabète de Type 1 ou LADA dans un sujet diagnostiqué avec Diabète de Type 1 ou LADA. Un kit de diagnostic de Diabète de Type 1 ou LADA dans un sujet comprenant des réactifs pour déterminer la présence D'anticorps dirigés contre l'insuline modifiée dans un échantillon provenant D'un sujet est également fourni.
Latest bibliographic data on file with the International Bureau